Maryland is currently home to 2666 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: University of Maryland Medical Center, Baltimore, Baltimore, Maryland
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
NCT06159166
Recruiting
This is a Phase 1/2a, open-label, non-randomized, multi-dose study of mirdametinib monotherapy in adults with NF1 and cNF. In both Phases of the study, participation in the study will comprise three periods: screening, treatment and post-study safety follow-up to be performed at the NF1 and cNF specialty center: Johns Hopkins University.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: NF1, Cutaneous Neurofibroma, Monotherapy
Register for Updates
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
NCT05973838
Recruiting
The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) and reduce polysubstance use among patients with OUD and polysubstance use in an underserved, rural area. The intervention is based on behavioral activation (BA) and is specifically designed to be implemented by a trained peer recovery specialist. In this hybrid, Type-1 effectiveness-implementation randomized co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Maryland Baltimore (UMD Drug Treatment Center), Baltimore, Maryland
Conditions: Polysubstance Addiction, Opioid Medication Assisted Treatment, Treatment Adherence, Retention in Care, Substance-Related Disorders
Register for Updates
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
NCT05777603
Recruiting
Background: Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate their lungs. These bacterial changes may aid tumor growth. Researchers want to find out if treating the bacteria, too, can help cancer treatment work better. Objective: To test 2 inhaled antibiotics (aztreonam and vancomycin), combined with a standard cancer treatment, in people with NSCLC. Eligibility: People aged 18 years and older w... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Advanced Non Small Cell Lung Cancer
Register for Updates
CT TAVR Abdomen Study
NCT05758701
Recruiting
A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specific... Read More
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
04/18/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Transcatheter Aortic Valve Replacement
Register for Updates
Nephrotic Syndrome Study Network
NCT01209000
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: Johns Hopkins Medical Institute, Baltimore, Maryland
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Register for Updates
Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults
NCT06733636
Recruiting
The goal of this clinical trial is to learn if ScentCare, a novel olfactory training device and accompanying companion web-based application, will lead to improved olfactory and well-being outcomes in elderly patients with Olfactory Dysfunction (OD). The main question it aims to answer is: - What effect does the olfactory training device (ScentCare) and accompanying companion web-based application have on olfaction? Researchers will compare ScentCare to solving Sudoku puzzles to see the effect... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/17/2025
Locations: Johns Hopkins Outpatient Center, Department of Otolaryngology - Head and Neck Surgery, Baltimore, Maryland
Conditions: Olfactory Dysfunction, Smell Loss, Anosmia, Hyposmia
Register for Updates
Studying TAK-243 in Patients With Advanced Cancer
NCT06223542
Recruiting
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) and in patients with lymphoma. TAK-243 is a drug that binds to and inhibits the ubiquitin-activating enzyme, an en... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
NCT05947383
Recruiting
This is a Phase 2, single-center study to explore the efficacy, safety, and tolerability of up to two 25-mg doses of psilocybin administered at an interval of 9 to 10 weeks in patients with MDD and cancer. This two-part study will administer a fixed dose (25 mg) of psilocybin in a double-blind, randomized, placebo-controlled portion (Dosing Session 1) and subsequently allow rollover into an open-label portion (Dosing Session 2; fixed dose of psilocybin, 25 mg) for patients who do not achieve rem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Sunstone Medical, PC, Rockville, Maryland
Conditions: Cancer, Major Depressive Disorder
Register for Updates
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
NCT05584826
Recruiting
The goal of this clinical trial is to assess feasibility, tolerability and preliminary effectiveness of MDMA-assisted therapy for adjustment disorder (AD) in 10 dyads of patients with cancer and a concerned significant other (CSO) (20 participants total). Participants will undergo an 8-week treatment period which will include two doses of MDMA, two Preparatory Sessions and four Integrative Sessions of non-drug therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Sunstone Medical, PC, Rockville, Maryland
Conditions: Cancer, Adjustment Disorders
Register for Updates
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
NCT03458832
Recruiting
The primary cause of facioscapulohumeral muscular dystrophy (FSHD), a common adult-onset dystrophy, was recently discovered identifying targets for therapy. As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures (FSHD-COM and EIM) and optimize eligibility crit... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Facioscapulohumeral Muscular Dystrophy
Register for Updates
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
NCT06796543
Recruiting
This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.
Gender:
ALL
Ages:
39 years and below
Trial Updated:
04/16/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Register for Updates